| Drug Name |
Pyridostigmine |
| Drug ID |
BADD_D01881 |
| Description |
Myasthenia gravis is an autoimmune disease involving dysfunction at the neuromuscular junction, most commonly due to autoantibodies directed against the acetylcholine receptor (AChR), which results in muscle tone loss, muscle weakness, and fatigue.[A231004] Acetylcholinesterase inhibitors have been the symptomatic treatment of choice in myasthenia gravis since the 1930s with the early use of [physostigmine] and [neostigmine]. By inhibiting the breakdown of acetylcholine in the neuromuscular junction, they increase signalling and relieve symptoms.[A231004, L32408, L32413] Pyridostigmine is the current drug of choice, with superior pharmacokinetics and reduced side effects compared to [neostigmine].[L32408, L32413] In addition to treating myasthenia gravis, pyridostigmine is used to reverse neuromuscular blocks, relieve symptoms in congenital myasthenic syndromes, and protect against certain nerve agents, notably during the Gulf War.[A231009, A231014, L32413, L32418]
Pyridostigmine was granted initial FDA approval on April 6, 1955, as an oral tablet. Possible dose forms have been expanded to include extended-release tablets, syrups, and injections, marketed under various brand and generic names.[L32408, L32413] |
| Indications and Usage |
For the treatment of myasthenia gravis. |
| Marketing Status |
Prescription; Discontinued |
| ATC Code |
N07AA02 |
| DrugBank ID |
DB00545
|
| KEGG ID |
C07410
|
| MeSH ID |
D011729
|
| PubChem ID |
4991
|
| TTD Drug ID |
D0O2WB
|
| NDC Product Code |
Not Available |
| Synonyms |
Pyridostigmine Bromide | Bromide, Pyridostigmine | Pyridostigmine | Mestinon |
